The Motley Fool Discussion Boards

Previous Page

Investing/Strategies / Short Term Trading


Subject:  gapper Date:  11/5/2013  9:48 AM
Author:  alcear Number:  36648 of 36748

Cytori Therapeutics Inc. (CYTX) unveiled a pact to commercialize the company's cell therapies for the cardiovascular, renal and diabetes markets in Australia and several Asian nations. Shares of Cytori soared 46% to $3.05 after hours, after the company said partner Lorem Vascular will pay up to $500 million in fees for a 30-year exclusive license to Cytori.
Copyright 1996-2018 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us